Phase 2 trial of trastuzumab and docetaxel in HER2-positive salivary duct carcinoma
In HER2-positive salivary duct carcinoma, an aggressive salivary cancer resembling breast cancer, trastuzumab plus docetaxel shrank tumours in 70 percent of patients, establishing HER2 testing and targeting in the disease.
Overview
Single-arm phase 2 study of 57 patients with HER2-positive locally advanced, recurrent or metastatic salivary duct carcinoma treated with trastuzumab and docetaxel.
Objective response was 70.2 percent with a median progression-free survival of 8.9 months and median overall survival of 39.7 months, with toxicity similar to the regimen's use in breast cancer.
- Objective response 70.2 percent.
- Median progression-free survival 8.9 months; median overall survival 39.7 months.
HER2 testing is standard in salivary duct carcinoma and trastuzumab-docetaxel a first-line option for HER2-positive advanced disease, with trastuzumab deruxtecan available at progression.
- Single-arm study in a rare disease.
- About 30 to 40 percent of salivary duct carcinomas are HER2-positive.
Similar pages
not linked directly; found by shared links- Key paperSystemic therapy in the palliative management of advanced salivary gland cancers (review)
Shares Salivary duct carcinoma, Journal of Clinical Oncology.
- Key paperCarboplatin-paclitaxel with or without trastuzumab in HER2-positive advanced or recurrent uterine serous carcinoma
Shares Journal of Clinical Oncology, Trastuzumab.
- Key paperGemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase 2 trial
Shares Journal of Clinical Oncology, Docetaxel.
- Key paperDESTINY-Lung02: two doses of trastuzumab deruxtecan in HER2-mutant metastatic non-small-cell lung cancer
Shares Journal of Clinical Oncology, Trastuzumab.
- TrialA Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
Shares Docetaxel, Trastuzumab.
- Key paperHER2CLIMB brain metastases analysis: intracranial efficacy and survival with tucatinib
Shares Journal of Clinical Oncology, Trastuzumab.
- TrialA Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or M
Shares Docetaxel, Trastuzumab.
- TrialA Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer
Shares Docetaxel, Trastuzumab.